AYA OMGYES Sexual Health Study
Launched by UNIVERSITY OF CHICAGO · Mar 4, 2025
Trial Information
Current as of May 11, 2025
Recruiting
Keywords
ClinConnect Summary
The AYA OMGYES Sexual Health Study is looking at how a web-based program called OMGYES.com can help young women who have survived cancer and are dealing with sexual dysfunction. This study aims to find out if the program is easy to use, accepted by participants, and suitable for their needs. Researchers will compare the experiences of women who start using the program right away with those who begin later, to see how it helps with their sexual health.
To be eligible for this study, participants must be between 18 and 40 years old, have been diagnosed with cancer at some point between the ages of 15 and 40, and currently be in complete remission for at least two months after major treatment. Participants will complete online modules from home and visit the clinic every five weeks to answer questionnaires about their experiences. This study is actively recruiting participants, and it's a great opportunity for those who meet the criteria to explore ways to improve their sexual health after cancer treatment.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age 18 to 40 years
- • Diagnosis of cancer between the ages of 15 and 40
- • Female genitalia, regardless of gender
- • Diagnosed with sexual dysfunction
- • Complete Remission and at least two months from a major treatment
- • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- • Ability to participate in study modules and to respond to surveys
- • Ability to understand and the willingness to sign a written informed consent document
- Exclusion Criteria:
- • Patients receiving other investigational agents
- • Patients expected to be neutropenic or have a significantly high infection risk that would exclude them from vaginal penetration
- • Patients who are unable complete the study intervention or surveys
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Adam DuVall, MD
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported